Author: Ravi Shankar

• Pauls Stradiņš Clinical University Hospital installs Genesis Robotic Magnetic Navigation System, establishing the first robotic program for the treatment of cardiac arrhythmia in Latvia
• First procedures successfully treated patients with a broad range of arrhythmia

ST. LOUIS, Oct. 22, 2026 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that Pauls Stradiņš Clinical University Hospital in Riga, Latvia, has established the first robotic center for the treatment of cardiac arrhythmias in Latvia and has successfully treated initial patients with the Genesis Robotic Magnetic Navigation System.

“The introduction of the advanced Genesis technology at Pauls Stradiņš Clinical University Hospital reflects the hospital’s long-term commitment to developing highly specialized, modern, and patient safety focused healthcare services,” said Prof. Andrejs Ērglis, Head of the Latvian Cardiology Center at Stradiņš Hospital and Professor of Medicine at the University of Latvia. “We are proud to make this technology available to the benefit of arrhythmia patients, allowing all patients to benefit from the precision, controlled catheter movement, and safety of robotics. We particularly see value in our robotic program expanding the potential to treat complex cardiac arrhythmia.”

Pauls Stradiņš Clinical University Hospital is Latvia’s premier hospital, academic and research center, with a strong reputation in cardiology excellence. The Genesis Robotic Magnetic Navigation system introduces the benefits of robotic precision and safety to cardiac ablation, a common minimally invasive procedure to treat arrhythmias. Tens of millions of individuals worldwide suffer from arrhythmias – abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, arrhythmia may significantly increase the risk of stroke, heart failure, and sudden cardiac arrest.

“We are delighted to establish this new robotic electrophysiology center of excellence with Pauls Stradiņš Clinical University Hospital,” said David Fischel, Chairman and CEO of Stereotaxis. “We look forward to collaborating with the hospital and cardiology team to advance patient care in Latvia and advance clinical science that will have a global impact.”

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.

Cautionary Note Regarding Forward-Looking Statements
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe”, “estimate”, “project”, “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to manage expenses at sustainable levels, our overall liquidity and our ability to fund operations, acceptance of the Company’s products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, our ability to manage and integrate recent acquisitions, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company’s periodic and other filings with the SEC. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this press release.

Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer

Kimberly Peery
Chief Financial Officer

314-678-6100
Investors@Stereotaxis.com

Recognition reflects three years of sustained growth in revenue, profits, and shareholder returns

BOCA RATON, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) — Red Violet, Inc. (NASDAQ: RDVT), a leading identity intelligence and analytics company, today announced that it has debuted at No. 43 on Fortune’s 2026 list of the 100 Fastest-Growing Companies. The ranking recognizes publicly traded companies that have delivered sustained growth in revenue, profits, and stock returns over a three-year period.

“We’re honored to be named to Fortune’s Fastest-Growing Companies list for the first time,” said Derek Dubner, red violet’s CEO. “This recognition reflects the combination that drives our business: differentiated, proprietary technology, a relentless focus on our customers, and a team that executes at a very high level. Delivering growth in revenue, profits, and shareholder returns is what we aim to do, and we believe we are still early in red violet’s evolution.”

Now in its 41st year, the annual ranking is based on a quantitative review of publicly traded companies. This is red violet’s first appearance on the list. It follows the company’s recognition in November 2025 as No. 107 of 500 companies on TIME’s inaugural America’s Growth Leaders ranking.

Ranking methodology

To qualify for the 2026 list, a company must trade on a major U.S. stock exchange, report in U.S. dollars, file quarterly reports with the SEC, and have traded continuously since June 30, 2023. It must have a minimum market capitalization of $225 million and a stock price of at least $5 on June 30, 2026, and latest-twelve-months revenue and net income, ended on or before April 30, 2026, of at least $50 million and $10 million, respectively. Companies must also have posted annualized growth in revenue and earnings per share of at least 15% over the three years ended on or before April 30, 2026. The full list and methodology are available at https://fortune.com/ranking/100-fastest-growing-companies/.

About red violet^®

At red violet, we build proprietary technologies and apply analytical capabilities to deliver identity intelligence. Our technology powers critical solutions, which empower organizations to operate with confidence. Our solutions enable the real-time identification and location of people, businesses, assets and their interrelationships. These solutions are used for purposes including identity verification, risk mitigation, due diligence, fraud detection and prevention, regulatory compliance, and customer acquisition. Our cloud-native, AI-embedded identity intelligence platform, CORE™, is purpose-built for the enterprise, yet flexible enough for organizations of all sizes, bringing clarity to massive datasets by transforming data into intelligence. Our solutions are used today to enable frictionless commerce, enhance safety, and mitigate fraud and the related financial losses borne by society. For more information, please visit www.redviolet.com.

Forward-Looking Statements

This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipate,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning. Such forward-looking statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations, including whether the Company will continue to deliver growth in revenue, profits, and shareholder returns as it continues to evolve. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release and are advised to consider the factors listed above together with the additional factors under the heading “Forward-Looking Statements” and “Risk Factors” in red violet’s SEC Filings. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Company Contact:
Camilo Ramirez
Red Violet, Inc.
561-757-4500
ir@redviolet.com

CATSKILL, N.Y., Oct. 22, 2026 (GLOBE NEWSWIRE) — Greene County Bancorp, Inc. (the “Company”) (NASDAQ: GCBC), the holding company for Bank of Greene (formerly the Bank of Greene County) and its subsidiary Greene County Commercial Bank, today reported net income for the three months ended September 30, 2026, which is the first quarter of the Company’s fiscal year ending June 30, 2027. Net income for the three months ended September 30, 2026 was $12.5 million, or $0.73 per basic and diluted share, as compared to $8.9 million, or $0.52 per basic and diluted share, for the three months ended September 30, 2025. Net income increased $3.6 million, or 40.9%, when comparing the three months ended September 30, 2026 and 2025.

Highlights:

• Net Income: $12.5 million for the three months ended September 30, 2026, a new record high
• Total Assets: $3.2 billion at September 30, 2026, a new record high
• Net Loans: $1.8 billion at September 30, 2026, a new record high
• Total Deposits: $2.8 billion at September 30, 2026, a new record high
• Return on Average Assets: 1.61% for the three months ended September 30, 2026
• Return on Average Equity: 17.73% for the three months ended September 30, 2026

“This quarter marked an important milestone as we introduced the Bank of Greene name and delivered record quarterly earnings,” said Donald Gibson, President & CEO. “Our new name reflects the broader region we serve and the relationships we continue to build across the Hudson Valley and Capital Region. Our commitment remains rooted in responsive personal service and local decision making. We are proud of our employees and remain focused on growing responsibly, supporting our customers, and delivering long-term shareholder value.”

Effective September 14, 2026, the Company’s primary banking subsidiary changed its legal name from the Bank of Greene County to Bank of Greene. The name change has no impact on the Bank’s operations and has no impact on the Company’s consolidated financial statements.

At the Company’s Annual Meeting on November 7, 2026, shareholders will consider a related proposal to amend the Company’s charter to change its legal name from Greene County Bancorp, Inc. to Greene Bancorp, Inc. If approved, the name change is expected to become effective following certification of the shareholder vote on November 9, 2026. The Company’s Nasdaq trading symbol “GCBC” and CUSIP number are not expected to change.

Total consolidated assets for the Company were $3.2 billion at September 30, 2026, primarily consisting of $1.8 billion of net loans and $1.2 billion of total securities available-for-sale and held-to-maturity. Consolidated deposits totaled $2.8 billion at September 30, 2026, consisting of retail, business, municipal and private banking relationships.

Pre-provision net income was $12.1 million for the three months ended September 30, 2026 as compared to $10.1 million for the three months ended September 30, 2025, an increase of $1.9 million, or 19.2%. Pre-provision net income measures the Company’s net income not including the provision for credit losses. Management believes that this non-GAAP measure assists investors in comprehending the impact of the provision for credit losses on the Company’s reported results, offering an alternative view of the Company’s performance and the Company’s ability to generate income in excess of its provision for credit losses.

The Company continues to manage its balance sheet with a focus on higher-yielding loans and securities, and disciplined deposit pricing. Deposit rates are actively managed in response to market interest rates and competitive conditions. These efforts contributed to a higher net interest margin for the three months ended September 30, 2026, compared with the same period in 2025.

Uncertainty surrounding inflation, the direction of interest rates, and geopolitical developments continues to influence the economic outlook. The Company remains focused on prudent risk management, maintaining financial strength and pursuing profitable growth, while delivering long-term shareholder value and serving the financial needs of its communities.

Selected highlights for the three months ended September 30, 2026, are as follows:

Net Interest Income and Margin

• Net interest income increased $4.4 million to $21.9 million for the three months ended September 30, 2026, from $17.5 million for the three months ended September 30, 2025. The increase in net interest income was primarily due to an increase in the average balance of interest-earning assets, which increased $159.3 million when comparing the three months ended September 30, 2026 and 2025, an increase in the average yield on interest-earning assets, which increased 16 basis points when comparing the three months ended September 30, 2026 and 2025, and a decrease in the average rate paid on interest-bearing liabilities, which decreased 30 basis points when comparing the three months ended September 30, 2026 and 2025. The increase in net interest income was offset by an increase in the average balance of interest-bearing liabilities, which increased $101.8 million when comparing the three months ended September 30, 2026 and 2025.

  Average loan balances increased $113.6 million and the yield on such loans increased 12 basis points when comparing the three months ended September 30, 2026 and 2025. The average balance of securities increased $58.4 million and the yield on such securities increased 24 basis points when comparing the three months ended September 30, 2026 and 2025. The average interest-bearing bank balances and federal funds decreased $14.6 million and the yield on interest-bearing bank balances and federal funds decreased 125 basis points when comparing the three months ended September 30, 2026 and 2025.

  The cost of NOW deposits decreased 39 basis points, the cost of certificates of deposits decreased 25 basis points, and the cost of savings and money market deposits decreased 4 basis points when comparing the three months ended September 30, 2026 and 2025. The growth in the average interest-bearing liabilities was primarily due to an increase in certificates of deposits of $51.8 million, an increase in average NOW deposits of $32.7 million, and an increase in average savings and money market deposits of $489,000 when comparing the three months ended September 30, 2026 and 2025. When comparing the three months ended September 30, 2026 and 2025, yields on interest-earning assets increased while the costs of interest-bearing deposits declined, reflecting continued asset repricing and the Company’s strategic reduction in deposit rates.

• Net interest rate spread increased 46 basis points to 2.71% for the three months ended September 30, 2026 as compared to 2.25% for the three months ended September 30, 2025.
  Net interest margin increased 45 basis points to 2.93% for the three months ended September 30, 2026 as compared to 2.48% for the three months ended September 30, 2025. The improvement reflected higher yields on loans and securities, combined with lower deposit costs, including reduced rates paid on NOW accounts and certificates of deposit. These benefits more than offset the decline in yields on interest-bearing bank balances and federal funds, supporting margin expansion alongside balance sheet growth.

• Net interest income on a taxable-equivalent basis includes the additional amount of interest income that would have been earned if the Company’s investment in tax-exempt securities and loans had been subject to federal and New York State income taxes yielding the same after-tax income. Tax-equivalent net interest margin increased 46 basis points to 3.24% for the three months ended September 30, 2026, from 2.78% for the three months ended September 30, 2025.

Credit Quality and Provision for Credit Losses

• Provision for credit losses amounted to a benefit of $432,000 for the three months ended September 30, 2026 as compared to a charge of $1.3 million for the three months ended September 30, 2025. The benefit for the three months ended September 30, 2026, was primarily attributable to the release of the allowance for credit losses associated with an individually evaluated loan that was repaid in full during the quarter, as well as improvements in the economic forecasts used in the Current Expected Credit Loss (“CECL”) model. The allowance for credit losses on loans to total loans receivable was 1.21% at September 30, 2026 as compared to 1.25% at June 30, 2026.
• Commercial and commercial real estate loans classified as substandard and special mention totaled $30.8 million at September 30, 2026, and $40.0 million at June 30, 2026, a decrease of $9.2 million. The decrease in the commercial and commercial real estate loans classified during the period ended September 30, 2026 was primarily due to upgrades of commercial real estate and commercial loans that were considered to be performing and paying in accordance with the terms of their loan agreements, and commercial real estate and commercial loans that were paid off during the period. Of the loans classified as substandard or special mention, $29.9 million were performing at September 30, 2026. There were no loans classified as doubtful or loss at September 30, 2026 or June 30, 2026.
• Net charge-offs on loans amounted to $48,000 and $60,000 for the three months ended September 30, 2026 and 2025, respectively, a decrease of $12,000. There were no material charge-offs in any loan segment during the three months ended September 30, 2026.
• Nonperforming loans amounted to $3.2 million at September 30, 2026 and $3.9 million at June 30, 2026. The activity in nonperforming loans during the period included $1.2 million in loan repayments, $163,000 in loans returning to performing status, $91,000 in charge-offs or transfers to foreclosure, and $720,000 of loans placed into nonperforming status. At September 30, 2026, nonperforming assets were 0.10% of total assets as compared to 0.12% at June 30, 2026. At September 30, 2026, nonperforming loans were 0.18% of net loans as compared to 0.23% at June 30, 2026.

Noninterest Income and Noninterest Expense

• Noninterest income decreased $1.1 million, or 27.0%, to $2.9 million for the three months ended September 30, 2026 as compared to $4.0 million for the three months ended September 30, 2025. The decrease during the three months ended September 30, 2026 was primarily due to a $1.2 million loss on sales of securities available-for-sale and a decrease of $289,000 in income earned on customer interest rate swaps. This was partially offset by a $140,000 increase in investment services income.

• Noninterest expense increased $740,000, or 7.4%, to $10.8 million for the three months ended September 30, 2026 as compared to $10.1 million for the three months ended September 30, 2025. The increase during the three months ended September 30, 2026 was primarily due to an increase of $582,000 in salaries and employee benefits and an increase of $367,000 in the allowance for credit losses unfunded commitment expense, due to an increase in the Company’s contractual obligation to extend credit.

Income Taxes

• Provision for income taxes reflects the expected tax associated with the pre-tax income generated for the given period and certain regulatory requirements. The effective tax rate was 13.4% for the three months ended September 30, 2026 and 12.9% for the three months ended September 30, 2025. The statutory tax rate is impacted by the benefits derived from tax-exempt bond and loan income, the Company’s real estate investment trust subsidiary income, income received on the bank owned life insurance and tax credits to arrive at the effective tax rate. The increase during the three months ended September 30, 2026 was primarily due to higher mix of pre-tax income and reflects a lower mix of tax-exempt income from municipal bonds, tax advantage loans, and bank owned life insurance in proportion to pre-tax income.

Balance Sheet Summary

• Total assets of the Company were $3.2 billion at September 30, 2026 and June 30, 2026.
• Total cash and cash equivalents for the Company were $135.0 million at September 30, 2026 and $144.9 million at June 30, 2026. The Company has continued to maintain strong capital and liquidity positions as of September 30, 2026.
• Securities available-for-sale and held-to-maturity increased $48.6 million, or 4.1%, to $1.23 billion at September 30, 2026 as compared to $1.18 billion at June 30, 2026. Securities purchased totaled $148.1 million during the three months ended September 30, 2026, primarily consisting of $125.2 million of state and political subdivision securities, $13.9 million of mortgage-backed securities, and $9.0 million of collateralized mortgage obligations. Principal pay-downs and maturities during the three months ended September 30, 2026, amounted to $87.0 million, primarily consisting of $66.8 million of state and political subdivision securities, $13.0 million of mortgage-backed securities, $3.0 million in U.S. Treasuries, $3.0 million in corporate debt securities, and $1.2 million of collateralized mortgage obligations.
• Net loans receivable increased $23.1 million, or 1.3%, to $1.8 billion at September 30, 2026 as compared to $1.7 billion at June 30, 2026. Loan growth experienced during the three months ended September 30, 2026, consisted primarily of $18.3 million in commercial real estate loans, $3.7 million in commercial loans, and $2.5 million in home equity loans. The allowance for credit losses on loans decreased $417,000, or 1.9%, to $21.4 million at September 30, 2026 as compared to $21.9 million at June 30, 2026. The decrease in the allowance for credit losses was primarily attributable to the release of the allowance for credit losses associated with an individually evaluated loan that was repaid in full during the quarter, as well as improvements in the economic forecasts used in the CECL model.
• Deposits totaled $2.8 billion at September 30, 2026 as compared to $2.7 billion at June 30, 2026, an increase of $134.4 million, or 5.0%. The Company had $41.6 million and $52.4 million of brokered deposits at September 30, 2026 and June 30, 2026, respectively. NOW deposits increased $111.3 million, or 5.6%, certificates of deposits increased $19.1 million, or 7.7%, and noninterest bearing deposits increased $13.9 million, or 9.9%, when comparing September 30, 2026 and June 30, 2026. Savings deposits decreased $5.5 million, or 2.3%, and money market deposits decreased $4.4 million, or 4.4%, when comparing September 30, 2026 and June 30, 2026.

• Borrowings amounted to $66.2 million at September 30, 2026 as compared to $155.1 million at June 30, 2026, a decrease of $88.9 million. At September 30, 2026, borrowings included $40.0 million of overnight borrowings with the Federal Home Loan Bank of New York (“FHLB”), $20.0 million of Fixed-to-Floating Rate Subordinated Notes and $6.2 million of long-term borrowings with the FHLB.

  As previously announced, on September 15, 2026, the Company redeemed $10.0 million in aggregate principal amount of the $30.0 million 3.00% Fixed-to-Floating Rate Subordinated Notes, due September 15, 2031. Following the redemption, $20.0 million in aggregate principal amount of the Notes remains outstanding. The redemption was funded by cash on hand.

• Shareholders’ equity increased to $286.0 million at September 30, 2026 as compared to $277.8 million at June 30, 2026, resulting primarily from net income of $12.5 million, partially offset by an increase in accumulated other comprehensive loss of $3.5 million and dividends declared and paid of $859,000. Under the Company’s current stock repurchase program, there were no repurchases during the three months ended September 30, 2026. As of the three months ended September 30, 2026, 398,657 shares remain in the stock repurchase program.

Corporate Overview

Greene County Bancorp, Inc. is the holding company for Bank of Greene, and its subsidiary Greene County Commercial Bank. The Company is the leading provider of community-based banking services throughout the Hudson Valley and Capital Region of New York State. Its customers include individuals, businesses, municipalities and other institutions. Greene County Bancorp, Inc. (GCBC) is publicly traded on the Nasdaq Capital Market and is dedicated to promoting economic development and a high quality of life in the communities it serves. For more information on Greene County Bancorp, Inc., visit www.bankofgreene.com.

Forward-Looking Statements

In addition to historical information, this earnings release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which describes the future plans, strategies and expectations of the Company. Forward-looking statements can be identified by the use of words such as “estimate,” “project,” “believe,” “intend,” “anticipate,” “assume,” “plan,” “seek,” “expect,” “will,” “may,” “should,” “indicate,” “would,” “contemplate,” “continue,” “target” and words of similar meaning. Forward-looking statements are based on our current beliefs and expectations and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control. In addition, these forward-looking statements are subject to assumptions with respect to future business strategies and decisions that are subject to change. Accordingly, you should not place undue reliance on such statements. We are under no duty to and do not take any obligation to update any forward-looking statements after the date of this report. Factors which could have a material adverse effect on the operations of the Company and its subsidiaries include, but are not limited to, changes in general economic conditions, interest rates and inflation; changes in asset quality; our ability to access cost-effective funding; fluctuations in real estate values; changes in laws or regulations; the effects of any federal government shutdown; changes in liquidity, including the size and composition of our deposit portfolio and the percentage of uninsured deposits in the portfolio; changes in technology; failures or breaches of our IT security systems; our ability to introduce new products and services and capitalize on growth opportunities; changes in accounting policies and practices; our ability to retain key employees; and the effects of natural disasters and geopolitical events, including terrorism, conflict and acts of war.

For more information, please see our reports filed with the United States Securities and Exchange Commission (“SEC”), including our most recent annual report on Form 10-K and quarterly reports on Form 10-Q.

Non-GAAP Measures

In addition to presenting information in conformity with accounting principles generally accepted in the United States of America (GAAP), this news release contains financial information determined by methods other than GAAP (non-GAAP). The following measures used in this release, which are commonly utilized by financial institutions, have not been specifically exempted by the Securities and Exchange Commission (“SEC”) and may constitute “non-GAAP financial measures” within the meaning of the SEC’s rules.

The Company has provided in this news release supplemental disclosures for the calculation of net interest margin utilizing a fully taxable-equivalent adjustment and pre-provision net income. Management believes that the non-GAAP financial measures disclosed by the Company from time to time are useful in evaluating the Company’s performance and that such information should be considered as supplemental in nature and not as a substitute for or superior to the related financial information prepared in accordance with GAAP. Our non-GAAP financial measures may differ from similar measures presented by other companies. Refer to the tables on page 9 for Non-GAAP to GAAP reconciliations.

Greene County Bancorp, Inc.
Consolidated Statements of Income and Selected Financial Ratios (Unaudited)

	At or for the Three Months
	Ended September 30,
Dollars in thousands, except share and per share data		2026			2025
Interest income	$34,598			$31,623
Interest expense		12,709			14,103
Net interest income		21,889			17,520
(Benefit) Provision for credit losses		(432	)		1,257
Noninterest income		2,909			3,986
Noninterest expense		10,801			10,061
Income before taxes		14,429			10,188
Tax provision		1,927			1,318
Net income	$12,502			$8,870
Basic and diluted EPS	$0.73			$0.52
Weighted average shares outstanding		17,025,485			17,026,828
Dividends declared per share (4)	$0.11			$0.10
Selected Financial Ratios
Return on average assets(1)		1.61%			1.21%
Return on average equity(1)		17.73%			14.59%
Net interest rate spread(1)		2.71%			2.25%
Net interest margin(1)		2.93%			2.48%
Fully taxable-equivalent net interest margin(2)		3.24%			2.78%
Efficiency ratio(3)		43.56%			46.78%
Non-performing assets to total assets		0.10%			0.12%
Non-performing loans to net loans		0.18%			0.22%
Allowance for credit losses on loans to non-performing loans		664.87%			597.92%
Allowance for credit losses on loans to total loans		1.21%			1.27%
Shareholders’ equity to total assets		8.82%			8.11%
Dividend payout ratio(4)		15.07%			19.23%
Actual dividends paid to net income(5)		6.87%			8.80%
Book value per share	$16.80			$14.58
(1) Ratios are annualized when necessary.
(2) Interest income calculated on a taxable-equivalent basis (non-GAAP) includes the additional interest income that would have been earned if the Company’s investment in tax-exempt securities and loans had been subject to federal and New York State income taxes yielding the same after-tax income.
(3) The efficiency ratio has been calculated as noninterest expense divided by the sum of net interest income and noninterest income.
(4) The dividend payout ratio has been calculated based on the dividends declared per share divided by basic earnings per share. No adjustments have been made to account for dividends waived by Greene County Bancorp, MHC (“MHC”), the Company’s majority shareholder, owning 54.1% of the shares outstanding.
(5) Dividends declared divided by net income. The MHC waived its right to receive dividends declared during the three months ended June 30, 2025, September 30, 2025, December 31, 2025, June 30, 2026, and September 30, 2026. Dividends declared during the three months ended March 31, 2026, were paid to the MHC.

Greene County Bancorp, Inc.
Consolidated Statements of Financial Condition (Unaudited)

	At September 30, 2026				At June 30, 2026
Dollars in thousands, except share data
Assets
Cash and due from banks	$24,519				$12,306
Interest-bearing deposits		110,480				132,599
Total cash and cash equivalents		134,999				144,905
Long-term certificate of deposit		1,225				1,225
Securities available-for-sale, at fair value		393,042				373,810
Securities held-to-maturity, at amortized cost, net of
allowance for credit losses of $467 and $530		832,982				803,553
Equity securities, at fair value		402				388
Federal Home Loan Bank stock, at cost		4,322				7,777
Loans receivable		1,776,011				1,753,342
Allowance for credit losses on loans		(21,442)				(21,859)
Net loans receivable		1,754,569				1,731,483
Premises and equipment, net		14,663				14,839
Bank owned life insurance		69,631				68,895
Foreclosed real estate		135				–
Accrued interest receivable		18,609				17,184
Prepaid expenses and other assets		18,041				19,368
Total assets	$3,242,620				$3,183,427
Liabilities and shareholders’ equity
Noninterest bearing deposits	$154,167				$140,229
Interest bearing deposits		2,693,675				2,573,170
Total deposits		2,847,842				2,713,399
Borrowings, short-term		40,000				119,000
Borrowings, long-term		6,166				6,166
Subordinated notes payable, net		20,000				29,979
Accrued expenses and other liabilities		42,629				37,052
Total liabilities		2,956,637				2,905,596
Total shareholders’ equity		285,983				277,831
Total liabilities and shareholders’ equity	$3,242,620				$3,183,427
Common shares outstanding		17,025,485				17,025,485
Treasury shares		197,195				197,195

The above information is preliminary and based on the Company’s data available at the time of presentation.

Non-GAAP to GAAP Reconciliations

The following table summarizes the adjustments made to arrive at the fully taxable-equivalent net interest margins.

		For the three months ended September 30,
(Dollars in thousands)			2026			2025
Net interest income (GAAP)		$21,889			$17,520
Tax-equivalent adjustment(1)			2,286			2,110
Net interest income-fully taxable-equivalent basis (non-GAAP)		$24,175			$19,630
Average interest-earning assets (GAAP)		$2,988,625			$2,829,350
Net interest margin-fully taxable-equivalent basis (non-GAAP)			3.24%			2.78%
(1) Interest income calculated on a taxable-equivalent basis (non-GAAP) includes the additional interest income that would have been earned if the Company’s investment in tax-exempt securities and loans had been subject to federal and New York State income taxes yielding the same after-tax income. The rate used for this adjustment was 21% for federal income taxes for the three months ended September 30, 2026 and 2025, 4.44% for New York State income taxes for the three months ended September 30, 2026 and 2025.

The following table summarizes the adjustments made to arrive at pre-provision net income.

	For the three months ended September 30,
(Dollars in thousands)		2026			2025
Net income (GAAP)	$12,502			$8,870
(Benefit) Provision for credit losses		(432)			1,257
Pre-provision net income (non-GAAP)	$12,070			$10,127

The above information is preliminary and based on the Company’s data available at the time of presentation.

For Further Information Contact:
Donald E. Gibson
President & CEO
(518) 943-2600
donaldg@bankofgreene.com

Nick Barzee
SVP & CFO
(518) 943-2600
nickb@bankofgreene.com

• Intravenous SCY-247 was generally well tolerated in healthy participants, with no drug-related serious adverse events
• Once-daily intravenous doses of 50 mg or higher achieved exposures at or above the target identified in murine models of invasive candidiasis
• Company expects to initiate Phase 2 development of SCY-247 in oral and IV formulations in 2027, subject to regulatory agreement
• SCY-247 development is advancing with the support of a BARDA contract providing up to approximately $214 million in non-dilutive funding if milestones are achieved

JERSEY CITY, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS”, or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced topline results from its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of the intravenous (IV) formulation of SCY-247, its second-generation triterpenoid (fungerp) antifungal candidate. SCY-247 is under development in both oral and intravenous (IV) formulations for the treatment and prevention of invasive fungal infections with the potential to provide therapeutic advantages by having activity against drug-resistant fungi.

“With Phase 1 studies of both the intravenous and oral formulations of SCY-247 now complete, we can refine our plans for the next stage of development of this second-generation fungerp, designed to address the growing threat of antimicrobial resistance,” said Todd Minga, M.D., SVP of Research and Development at Scynexis. “Having both intravenous and oral formulations could provide flexibility in managing patients with invasive candidiasis and those at risk of invasive fungal diseases. We look forward to initiating a Phase 2 study next year, subject to agreement with the FDA.”

Recently, Scynexis was awarded a BARDA contract (75A50126C00007) providing up to approximately $214 million in non-dilutive funding, if milestones are achieved, to advance the development of SCY-247. The award is structured as a cost-share arrangement, with BARDA providing support for eligible SCY-247 costs. The Company expects to fund its share of near-term program costs for SCY-247 within its existing operating plan. The Company’s previously communicated development plans for SCY-770 to initiate a Phase 2 study in the fourth quarter of 2026 and the Company’s projected cash runway into 2029 remain unchanged.

Phase 1 Study Results

The study evaluated the safety and characterized the pharmacokinetics of intravenous SCY-247 to inform progression to, and dose selection for, a Phase 2 study in patients with invasive candidiasis. The Phase 1 study enrolled 56 healthy participants across seven cohorts: 42 received SCY-247 by peripheral intravenous infusion and 14 received placebo. The study evaluated single ascending doses up to 300 mg and multiple ascending doses administered once daily for seven days up to 200 mg.

SCY-247 administered by peripheral intravenous infusion was generally well tolerated. The most commonly reported adverse reactions were mild to moderate erythema and pain at the infusion site. There were no drug-related serious adverse events or discontinuations due to a related adverse event.

Intravenous doses of 50 mg once daily or higher achieved exposures at or above the efficacy target identified in murine models of invasive candidiasis (AUC_0–24 of 20 µg·h/mL). A previously completed Phase 1 study indicated that oral doses of 100 mg or higher are also anticipated to achieve the target exposure for efficacy. Overall, the safety, tolerability, and pharmacokinetic profile observed in this study support the continued clinical development of SCY-247. Further details of the results from this study will be presented at an upcoming scientific meeting.

Invasive candidiasis is associated with high mortality, and resistance to the limited available antifungal options is making treatment increasingly challenging. Designed to address these limitations, SCY-247 has demonstrated in vitro and in vivo activity against several challenging Candida strains, including Candida auris, as well as most azole- and echinocandin-resistant strains. SCY-247 has been granted Orphan Drug, Qualified Infectious Disease Product (QIDP) and Fast Track designations by the U.S. Food and Drug Administration.

Future activities for this project may be funded in whole or in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Center for the Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50126C00007.

About SCY-247

SCY-247 is a second-generation triterpenoid (fungerp) antifungal candidate being developed for the treatment of invasive candidiasis and the prevention of invasive fungal diseases. As a member of a novel structural class, SCY-247 has a differentiated mechanism of action from existing antifungal classes and has demonstrated in vitro activity against a broad range of fungal pathogens, including strains resistant to currently available therapies. SCY-247 has been granted Orphan Drug, Qualified Infectious Disease Product (QIDP) and Fast Track designations by the U.S. Food and Drug Administration. Recently, Scynexis was awarded a BARDA contract (75A50126C00007) providing up to approximately $214 million in non-dilutive funding to advance the development of SCY-247.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases. SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. SCYNEXIS’s proprietary antifungal platform “fungerps” includes BREXAFEMME® (ibrexafungerp tablets), the first approved representative of this novel class, which has been licensed to GSK, and SCY-247, currently in clinical stages of development for the treatment and prevention of invasive fungal diseases. For more information, visit www.scynexis.com.

Forward-Looking Statements

Statements contained in this press release regarding expected future events or results are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding: the Company’s expectation to initiate Phase 2 development of SCY-247 in oral and IV formulations in 2027, subject to regulatory agreement; the potential for SCY-247 to provide therapeutic advantages of both an oral and IV formulation; the amount and timing of any BARDA funding (under contract 75A50126C00007);   the Company’s expectation to fund its share of near-term program costs for SCY-247 within its existing operating plan; the anticipated initiation of the SCY-770 Phase 2 study in Q4 of 2026; the statements concerning the Company’s cash runway into 2029, and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks inherent in regulatory and other costs in developing products, including the risk that SCYNEXIS may not reach alignment with the FDA on the planned Phase 2 study designs on the anticipated timelines or at all, and the risk that BARDA does not exercise one or more options under the BARDA contract (75A50126C00007). For the Company, this includes the future prospects of the Company’s SCY-247 and SCY-770 programs, the timing and results of the Company’s anticipated Phase 2 clinical studies, stock price volatility and uncertainties relating to the financial markets, the medical community and the global economy, and the impact of instability in general business and economic conditions, including changes in inflation and interest rates. These and other risks are described more fully in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including without limitation, its most recent Annual Report on Form 10-K filed on March 4, 2026, including under the caption “Risk Factors,” and in other filings the Company makes with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

CONTACT: 
Investor Relations
John Fraunces
LifeSci Advisors
Tel: 917-355-2395
jfraunces@lifesciadvisors.com

Approximately 22-day field program to be managed by Lonquist, with results to feed 3D gravity inversion and 2D modelling along key seismic profiles

VANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) — Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that it has secured the approvals, permits and land access permissions required to commence its planned ground gravity survey at the Robinsons River Salt Project in Newfoundland and Labrador. The current survey design comprises approximately 500 planned measurement stations, with field acquisition expected to be undertaken by McKeown Exploration Services under the management of Lonquist Field Service (Canada), ULC (“Lonquist”). The survey will target gaps in existing gravity coverage and areas of exploration interest across the Project, including areas west of the Cloverleaf target and within the eastern block. Planned stations include traverses along selected historical seismic lines, allowing the new gravity measurements to be evaluated alongside existing seismic interpretations. Field acquisition is estimated to require approximately 22 working days, with final station locations and timing subject to access, weather and ground conditions, and completion of contractor arrangements.

The Mineral Lands Division of Newfoundland and Labrador’s Department of Energy and Mines approved the proposed geophysical survey program through Letter of Acceptance E260510, dated October 16, 2026. The survey will be conducted in accordance with the letter’s conditions, including in regard to environmental protection and archaeological requirements.

The Company aims to compare the new measurements with the Project’s historical airborne gravity-gradiometry data to assess consistency between the datasets, with the goal of improving confidence in the subsurface interpretation. The Company is planning to subsequently complete a modelling program that would include three-dimensional gravity inversion and targeted two-dimensional modelling along key seismic profiles near potential drilling locations. This work is intended to refine the interpretation of prospective salt structures and support decisions on future exploration drilling.

“We now have a detailed survey plan that builds directly on the technical work completed at Robinsons River,” said Paul Sparkes, Chief Executive Officer of Vortex. “These additional measurements will help us better understand the priority target areas and make more informed decisions about where to focus the next phase of exploration.”

The program advances the ground gravity survey announced on September 3, 2026, and Lonquist’s engagement announced on September 14, 2026. Vortex will provide further updates as fieldwork progresses. Gravity interpretations are non-unique and require integration with geological and drilling information; gravity data alone cannot establish salt composition, thickness or continuity.

Figure 1. Planned ground gravity station locations relative to the Robinsons River project licences and historical seismic lines. Station locations remain subject to field conditions and access.

Qualified Person

The scientific and technical information contained in this news release has been reviewed and approved by Jared Suchan, Ph.D., P.Geo., Vice President of Exploration of the Company and a “Qualified Person” as defined by National Instrument 43-101.

For additional information concerning the Project and the Company’s data-verification and quality-assurance procedures, readers are referred to the Company’s technical report entitled Independent Technical Report on the Robinsons River Salt Property, dated July 31, 2023, available under the Company’s profile on SEDAR+.

About Vortex Energy Corp.

Vortex Energy Corp. is an exploration stage company engaged principally in the acquisition, exploration, and development of mineral properties in North America. The Company is currently advancing its Robinson River Salt Project comprised of a total of 942 claims covering 23,500 hectares located approximately 35 kilometres south of the town of Stephenville in the Province of Newfoundland & Labrador. The Robinson River Salt Project is prospective for both salt and hydrogen salt cavern storage. The Company is also currently advancing its Fire Eye Uranium Property in the Athabasca Basin, a region renowned for its uranium deposits.

On Behalf of the Board of Directors

Paul Sparkes

Chief Executive Officer, Director

+1 (778) 819-0164

info@vortexenergycorp.com

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking information relates to future events or future performance and reflects management’s current expectations or beliefs regarding future events. Forward-looking information is often identified by words such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “potential”, “should”, “will” and similar expressions, or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. In particular, this press release contains forward-looking information regarding, among other things: the commencement, conduct, scope, timing and completion of the planned ground gravity survey at the Robinsons River Salt Project (the “Project”); the number and final locations of measurement stations; the engagement, availability and performance of Lonquist Field Service (Canada), ULC and McKeown Exploration Services; the Company’s ability to satisfy the conditions of applicable approvals and permits and obtain and maintain required land access; the anticipated duration of field acquisition; the collection, processing, interpretation and integration of new gravity measurements with historical airborne gravity-gradiometry, seismic, geological and drilling information; the completion of three-dimensional gravity inversion and targeted two-dimensional modelling; the ability of the survey and modelling to improve confidence in subsurface interpretations, refine prospective salt structures and support the selection of potential drilling locations and decisions regarding future exploration drilling; and the provision of further updates as fieldwork progresses. 

Forward-looking information is based on assumptions that management considers reasonable as of the date of this press release, including, without limitation, assumptions that: the Company will have sufficient financial, technical and personnel resources to carry out the planned program; contractor arrangements will be completed and the contractors will be available and perform as anticipated; all required approvals, permits and land access permissions will remain in good standing and their conditions will be satisfied; field access, weather and ground conditions will permit the survey to proceed substantially as planned; the planned stations can be surveyed and reliable data can be collected, processed and interpreted; historical datasets are sufficiently accurate, complete and compatible for the contemplated comparisons and modelling; the survey and modelling will generate information useful for refining the Company’s geological interpretation and future exploration planning; and there will be no material adverse change in applicable laws, regulatory requirements, commodity or capital-market conditions, or the Company’s business and financing plans. 

Although management believes that the assumptions and expectations reflected in such forward-looking information are reasonable, there can be no assurance that they will prove to be correct. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such information. These risks and uncertainties include, without limitation: the survey may be delayed, modified, suspended or not completed due to contractor availability or performance, access restrictions, weather, ground conditions, equipment failure, safety or logistical issues, cost escalation, financing constraints, regulatory requirements or other circumstances; approvals, permits or land access permissions may be amended, suspended, revoked or subject to additional conditions; final station locations, survey coverage and timing may differ from those currently contemplated; collected data may be incomplete, inconsistent, of insufficient quality or incapable of being integrated with historical datasets; gravity interpretations are non-unique and may not accurately identify the geometry, composition, thickness, continuity or economic significance of subsurface features; the contemplated inversion and modelling may not be completed, may produce inconclusive or unexpected results, or may not identify suitable drilling targets; historical exploration information may be inaccurate, incomplete or not independently verifiable; exploration results may not support further work, drilling or development; future exploration programs may not be approved, financed or completed; costs may exceed estimates; and risks inherent in mineral exploration and development, including geological uncertainty, environmental and archaeological requirements, community and stakeholder considerations, changes in laws or regulatory requirements, and the availability of capital, personnel, equipment and services. Additional risks are described in the Company’s continuous disclosure filings available under its profile on SEDAR+. Readers are cautioned that the foregoing list is not exhaustive. The forward-looking information contained in this press release is made as of the date hereof. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Readers should not place undue reliance on forward-looking information. The forward-looking information contained in this press release is expressly qualified by this cautionary statement. 

The Canadian Securities Exchange has not reviewed, approved, or disapproved the contents of this press release.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b3a03ba2-9c45-437c-ba72-32cb85aeff53

STOUGHTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it will report third quarter 2026 financial results before the market opens on Thursday November 5, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET.

Conference Call Information 
To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q3 2026 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: www.collegiumpharma.com. The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical is a dynamic biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system (CNS) and pain conditions.  Collegium has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions.    

With a portfolio of differentiated ADHD medications, anchored by JORNAY PM^® (methylphenidate HCl) CII and AZSTARYS^® (serdexmethylphenidate and dexmethylphenidate) CII, and an established leadership position in responsible pain management, Collegium leads with the scientific rigor and commercial expertise to deliver treatment options around how people live their lives.  

For more information, please visit collegiumpharma.com or find us on LinkedIn.   

Investor Contacts:
Ian Karp
Head of Investor Relations
ir@collegiumpharma.com

Media Contact:
Jessica Cotrone
Senior Vice President, Communications & Corporate Affairs
communications@collegiumpharma.com

WOBURN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will host a conference call on Wednesday, October 28, 2026, at 8:00 a.m. ET to discuss its financial results and provide corporate update for the fiscal second quarter ended September 30, 2026.

Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer section should use this link. A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.

About Replimune

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is intended to ignite local activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to then activate a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.

Investor Inquiries
Chris Brinzey
ICR Healthcare
339.970.2843
chris.brinzey@icrhealthcare.com

Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com

The company’s L-Series timing devices are designed to scale between COTS and traditional space-grade solutions, offering shorter lead times at competitive price points

CHANDLER, Ariz., Oct. 22, 2026 (GLOBE NEWSWIRE) — Microchip Technology (Nasdaq: MCHP) today announces the expansion of its L-Series of timing devices with the launch of its LX-820 Radiation-Tolerant Quartz Oscillator, designed for Low Earth Orbit (LEO) and other space applications. The L-Series portfolio provides satellite developers with a wide range of oscillator architectures to select from, each with varying frequency stability, phase noise, power and size, catering to different mission requirements.

The L-Series is positioned between commercial off-the-shelf (COTS) oscillators and traditional high-reliability space products, combining commercial- or military-grade components with production inspection, electrical and thermal analysis and hybrid manufacturing. The L-Series oscillators have passed Total Ionizing Dose (TID) and Single-Event Latchup (SEL) testing as complete, functioning devices, with radiation tolerance up to 50 krad and SEL testing to 40 MeV·cm²/mg. Additionally, most L-Series products also use swept quartz to reduce radiation-induced frequency drift. The L-Series OCXOs incorporate ruggedized construction and four-point crystal mounts designed to survive launch and the intended mission profile.

Designed to address two persistent challenges for satellite developers, the L-Series helps ease supply chain constraints while reducing budget pressure. Many timing solutions qualified for space environments have extended lead times and significant procurement costs. The L-Series is designed to provide a more accessible alternative, with many configurations available from stock or with lead times of less than 20 weeks. Additionally, the L-Series oscillators may lower overall program costs by reducing the need for the component pedigree, documentation requirements and inspection overhead that are typically associated with traditional high-reliability space-grade timing products.

“Satellite developers should not have to choose between dependable precision timing and the cost and schedule requirements of their mission,” said Randy Brudzinski, corporate vice president of Microchip’s frequency and time systems business unit. “Our L-Series oscillators bring together the performance, radiation tolerance and supply availability our customers need to confidently deploy their New Space applications using a precision timing solution that helps reduce both schedule and mission risk.”

The new LX-820 is available in a compact 3.2 mm × 2.5 mm surface-mount package and is designed to operate across a wide temperature range from -55°C to 125°C. The rugged device is engineered to meet MIL-PRF-55310 Level B and provides ±100 ppm performance. Additionally, the LX-820 supports CMOS output frequencies from 1.25 MHz to 135 MHz and low-voltage differential signaling (LVDS) output frequencies from 100 MHz to 250 MHz.

Modern satellite systems rely on highly accurate timing references to support communications, navigation, Earth observation, mapping and emerging lunar missions. As these applications can have different timing requirements, Microchip’s L-Series encompasses crystal oscillators (XOs), temperature-compensated crystal oscillators (TCXOs), oven-controlled crystal oscillators (OCXOs) and a pulse-per-second (PPS) disciplined oscillator. These products allow developers to use compact XOs where size and broad frequency coverage are priorities, TCXOs where tighter temperature stability and lower power are needed, OCXOs for more demanding stability and phase-noise requirements, and a disciplined oscillator where PPS synchronization and holdovers are required.

Microchip offers an extensive portfolio of clock and timing systems, ranging from miniature component oscillators, to small plug-in timing server cards, to atomic clocks and multi-rack time scale systems. As a primary contributor to the world’s time, Microchip’s timing solutions are trusted, reliable and resilient. For more information, visit Microchip’s clock and timing solutions webpage.

Pricing and Availability

The LX-820 Crystal Oscillator and other L-Series oscillators are now available in production quantities. For additional information and to purchase, contact a Microchip sales representative or authorized worldwide distributor.

Resources

High-res images available through Flickr or editorial contact (feel free to publish):

• Application image: www.flickr.com/photos/microchiptechnology/55522445284/sizes/l

About Microchip Technology:
Microchip Technology Inc. is a broadline supplier of semiconductors committed to making innovative design easier through total system solutions that address critical challenges at the intersection of emerging technologies and durable end markets. Its easy-to-use development tools and comprehensive product portfolio supports customers throughout the design process, from concept to completion. Headquartered in Chandler, Arizona, Microchip offers outstanding technical support and delivers solutions across the industrial, automotive, consumer, aerospace and defense, communications and computing markets. For more information, visit the Microchip website at www.microchip.com.

Note: The Microchip name and logo and the Microchip logo are registered trademarks of Microchip Technology Incorporated in the U.S.A. and other countries. All other trademarks mentioned herein are the property of their respective companies.

Editorial Contact:
Kim Dutton
kim.dutton@microchip.com

NEW YORK, Oct. 22, 2026 (GLOBE NEWSWIRE) — Teads Holding Co. (NASDAQ: TEAD), announced today that the company will release its third quarter 2026 results before the market opens on Thursday, November 5, 2026, followed by a conference call at 8:30 a.m. (Eastern Time) that same day to discuss the company’s results and business outlook.

The conference call can be accessed live over the phone by dialing 1-800-717-1738 or for international callers,1-646-307-1865. A replay will be available three hours after the call and can be accessed by dialing 1-877-660-6853, or for international callers, 1-201-612-7415. The passcode for the live call and replay is 13763331. The replay will be available until November 19, 2026.

Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of the Company’s website at https://investors.teads.com/. The online replay will be available for a limited time shortly following the call.

About Teads

Teads Holding Co. (“Teads”) (Nasdaq: TEAD) is a leading omnichannel advertising platform focused on driving outcomes for brand and performance advertisers across screens. With a focus on meaningful business outcomes for full funnel objectives, Teads drives value by leveraging predictive AI technology to connect quality media, beautiful brand creative, and context-driven addressability and measurement. Teads is directly partnered with more than 10,000 publishers and 20,000 advertisers globally. The company is headquartered in New York, New York, with a global team of around 1,700 people in 30+ countries.

For more information, visit www.teads.com.

Media Contact

press@teads.com

Investor Relations Contact

IR@teads.com

(332) 205-8999

Delivered Record First Quarter Operating Income, Up 28 Percent Year-Over-Year
Strong Results Reflect Productivity Improvements, Mix Optimization and Benefits from Pricing Actions
Realized Adjusted Operating Margin in Specialty Alloys Operations Segment of 37.7 Percent
Demand Accelerating in Commercial Aerospace Supply Chain, Resulting in Increased Bookings

PHILADELPHIA, Oct. 22, 2026 (GLOBE NEWSWIRE) — Carpenter Technology Corporation (NYSE: CRS) (the “Company”) today announced financial results for the fiscal first quarter ended September 30, 2026. For the quarter, the Company reported operating income of $196.4 million and earnings per diluted share of $3.25.

First Quarter Fiscal Year 2027 Highlights

• Delivered $196.4 million of operating income, up 28 percent year-over-year and down 5 percent sequentially
• Sequential performance reflects productivity improvements, mix management and benefits from pricing actions, offset by planned downtime for preventive maintenance activities
• Generated Specialty Alloys Operations (“SAO”) segment operating income of $216.3 million, up 27 percent year-over-year and down 6 percent sequentially
• Delivered adjusted operating margin of 37.7 percent in the SAO segment, up from 32.0 percent in the prior year first quarter and in line with 37.8 percent in the fourth quarter of fiscal year 2026
• Strong bookings for Commercial Aerospace, led by aerospace structural and distribution sub-markets which saw bookings increase 23 percent sequentially and 49 percent year-over-year
• Executed $133.9 million in share repurchases against repurchase programs; announced additional $1.0 billion share repurchase program in August 2026
• Realized earnings per diluted share of $3.25 in the quarter
• Generated $52.8 million of cash from operating activities

Outlook

• For the second quarter of fiscal year 2027, anticipate between $192 million to $197 million in operating income
• Maintain fiscal year 2027 operating income outlook in the range of $850 million to $880 million, representing a 21 percent to 25 percent increase over fiscal year 2026 operating income
• Well positioned for continued growth beyond fiscal year 2027 with strong market demand for our broad portfolio of specialized solutions, ongoing productivity improvements, product mix optimization, and realization of pricing actions

“Carpenter Technology delivered another strong quarter, generating $196.4 million of operating income in the first quarter of fiscal year 2027,” said Tony R. Thene, Chairman, President and CEO of Carpenter Technology. “This was the most profitable first quarter in the Company’s history, up 28 percent over the first quarter of fiscal year 2026, establishing a strong foundation for the rest of the fiscal year. The results, driven by productivity improvements, mix management and the benefits of pricing actions, were impressive for a quarter with increased preventive maintenance activities. Specifically, the SAO segment delivered $216.3 million of operating income and adjusted operating margin of 37.7 percent in the quarter, both significant increases over the previous year first quarter.”

“Notably, in the current quarter we saw a step up in demand, especially in the commercial aerospace supply chain. Customers in the aerospace structural and distribution sub-markets have increasing confidence in the industry’s ability to ramp and our engine customers are increasing activity to support new builds and elevated MRO activity. As a result, we saw increased sequential bookings across the commercial aerospace sub-markets, with the aerospace structural and distribution sub-markets leading the way. Further, in the strong demand environment, pricing continues to strengthen across our business.”

“We maintain our recently communicated fiscal year 2027 operating income outlook of $850 million to $880 million and our fiscal year 2029 operating income target of $1.2 billion to $1.3 billion which reflects the accelerating demand environment, continued benefits of pricing actions and the expected contribution from our brownfield capacity expansion project.”

“In addition, we are currently working on specific actions and projects to exceed our operating income targets for fiscal year 2027 and fiscal year 2029. With macro trends so strong and accelerating, we see additional upside to demand, pricing opportunity and productivity improvement that could drive our operating income even higher.”

“Altogether, we believe we have a compelling value creation story. We are delivering record results today with strong operating margins and levers to expand margins further, we see accelerating demand across our key end-use markets, and we continue to benefit from pricing actions. As a result, we have a clear path to significant earnings growth over the next several years, and we are positioned to create substantial long-term value for our shareholders.”

Financial Highlights

		Q1				Q4			Q1
($ in millions, except per share amounts)		FY2027				FY2026			FY2026
Net sales		$	798.2			$	851.0		$	733.7
Net sales excluding surcharge (a)		$	634.8			$	679.7		$	603.1
Operating income		$	196.4			$	206.9		$	153.3
Net income		$	162.5			$	162.4		$	122.5
Earnings per diluted share		$	3.25			$	3.23		$	2.43
Net cash provided from operating activities		$	52.8			$	240.1		$	39.2
Free cash flow (a)		$	(24.8	)		$	155.0		$	(3.4	)
(a) Non-GAAP financial measures explained in the attached tables

Net sales for the first quarter of fiscal year 2027 were $798.2 million, compared with $733.7 million in the first quarter of fiscal year 2026, an increase of $64.5 million (or 9 percent). Net sales excluding surcharge were $634.8 million for the current quarter, an increase of $31.7 million (or 5 percent) from the same period a year ago.

Operating income for the first quarter of fiscal year 2027 was $196.4 million compared to operating income of $153.3 million in the prior year period. Earnings per diluted share for the first quarter of fiscal year 2027 was $3.25 compared to earnings of $2.43 per diluted share in the prior year first quarter.

Cash provided from operating activities in the first quarter of fiscal year 2027 was $52.8 million, compared to $39.2 million in the same quarter last year. Free cash flow in the first quarter of fiscal year 2027 was negative $24.8 million, compared to negative $3.4 million in the same quarter last year. The increase in operating cash flow in the first quarter of fiscal year 2027 reflects higher earnings partially offset by changes in working capital, primarily inventory, compared to the same quarter last year. The unfavorable change in free cash flow reflects increased capital expenditures compared to the prior year period, namely from the brownfield expansion. Capital expenditures were $77.7 million in the first quarter of fiscal year 2027 compared to $42.6 million in the same quarter last year.

During the quarter ended September 30, 2026, the Company purchased 241,924 shares of its common stock on the open market for an aggregate of $133.9 million. As of September 30, 2026, $985.0 million remains available for future purchases under the $1.0 billion share repurchase program authorized in August 2026.

Total liquidity, including cash and available revolver balance, was $658.6 million at the end of the first quarter of fiscal year 2027. This consisted of $159.5 million of cash and $499.1 million of available borrowings under the Company’s Credit Facility.

Conference Call and Webcast Presentation

Carpenter Technology will host a conference call and webcast presentation today, October 22, 2026, at 10:00 a.m. ET, to discuss the financial results of operations for the first quarter of fiscal year 2027. Please dial +1 (833) 461-5787 for access to the live conference call. Access to the live webcast will be available at Carpenter Technology’s website (https://www.carpentertechnology.com), and a replay will soon be made available at https://www.carpentertechnology.com. Presentation materials used during this conference call will be available for viewing and download at https://www.carpentertechnology.com.

Non-GAAP Financial Measures

This press release includes discussions of financial measures that have not been determined in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). A reconciliation of the non-GAAP financial measures to their most directly comparable financial measures prepared in accordance with GAAP, accompanied by reasons why the Company believes the non-GAAP measures are important, are included in the attached schedules.

About Carpenter Technology

Carpenter Technology Corporation is a recognized leader in high-performance specialty alloy materials and process solutions for critical applications in the aerospace and defense, medical, energy, transportation, and industrial and consumer markets. Founded in 1889, Carpenter Technology has evolved to become a pioneer in premium specialty alloys including nickel, cobalt, and titanium and material process capabilities that solve our customers’ current and future material challenges. More information about Carpenter Technology can be found at https://www.carpentertechnology.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among other things, statements regarding guidance, outlook, targets, objectives, future operating performance, cash generation, capital allocation, market conditions and strategic initiatives. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ from those projected, anticipated, expected or implied. The most significant of these uncertainties are described in Carpenter Technology’s filings with the Securities and Exchange Commission, including its report on Form 10-K for the fiscal year ended June 30, 2026, and the exhibits attached to that filing. They include but are not limited to: (1) the cyclical nature of the specialty materials business and certain end-use markets, including aerospace, defense, medical, energy, transportation, industrial and consumer, or other influences on Carpenter Technology’s business such as new competitors, the consolidation of competitors, customers, and suppliers or the transfer of manufacturing capacity from the United States to foreign countries; (2) the ability of Carpenter Technology to achieve cash generation, growth, earnings, profitability, operating income, cost savings and reductions, qualifications, productivity improvements or process changes; (3) the ability to recoup increases in the cost of energy, raw materials, freight or other factors; (4) domestic and foreign excess manufacturing capacity for certain metals; (5) fluctuations in currency exchange and interest rates; (6) the effect of government trade actions, including tariffs; (7) the valuation of the assets and liabilities in Carpenter Technology’s pension trusts and the accounting for pension plans; (8) possible labor disputes or work stoppages; (9) the potential that our customers may substitute alternate materials or adopt different manufacturing practices that replace or limit the suitability of our products; (10) the ability to successfully acquire and integrate acquisitions; (11) the availability of credit facilities to Carpenter Technology, its customers or other members of the supply chain; (12) the ability to obtain energy or raw materials, especially from suppliers located in countries that may be subject to unstable political or economic conditions; (13) Carpenter Technology’s manufacturing processes are dependent upon highly specialized equipment located primarily in facilities in Reading and Latrobe, Pennsylvania and Athens, Alabama for which there may be limited alternatives if there are significant equipment failures or a catastrophic event; (14) the ability to hire and retain a qualified workforce and key personnel, including members of the executive management team, management, metallurgists and other skilled personnel; (15) fluctuations in oil and gas prices and production; (16) the impact of potential cybersecurity incidents, ransomware attacks, malicious AI usage, operational technology disruptions, information technology failures, data security breaches and failures of third-party technology service providers; (17) the ability of suppliers, logistics providers and other supply-chain participants to meet obligations due to capacity constraints, transportation disruptions, energy shortages, geopolitical events, labor shortages or other factors; (18) the ability to meet increased demand, production targets or commitments; (19) the ability to manage the impacts of natural disasters, climate change, pandemics and outbreaks of contagious diseases and other adverse public health developments; (20) geopolitical, economic, regulatory and security risks relating to our global business, including international conflicts, military actions, diplomatic tensions, trade restrictions, sanctions, disruptions to transportation corridors and shipping routes and changes in U.S. and foreign trade, tax and regulatory requirements; (21) challenges affecting the commercial aviation industry or key participants; (22) the consequences of the announcement, maintenance or use of Carpenter Technology’s share repurchase program; and (23) the ability to successfully execute major capital projects and brownfield expansion initiatives, including achieving expected costs, schedules, capacity additions, productivity improvements and returns on investment. Any of these factors could have an adverse and/or fluctuating effect on Carpenter Technology’s results of operations. The forward-looking statements in this document are intended to be subject to the safe harbor protection provided by Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. We caution you not to place undue reliance on forward-looking statements, which speak only as of the date of this press release or as of the dates otherwise indicated in such forward-looking statements. Carpenter Technology undertakes no obligation to update or revise any forward-looking statements.

PRELIMINARY CONSOLIDATED STATEMENTS OF OPERATIONS (in millions, except per share data) (Unaudited)
		Three Months Ended
		September 30,
			2026				2025
NET SALES		$	798.2			$	733.7
Cost of sales			541.9				517.3
Gross profit			256.3				216.4
Selling, general and administrative expenses			59.9				63.1
Operating income			196.4				153.3
Interest expense, net			7.1				11.5
Other income, net			(3.1	)			(3.0	)
Income before income taxes			192.4				144.8
Income tax expense			29.9				22.3
NET INCOME		$	162.5			$	122.5
EARNINGS PER COMMON SHARE:
Basic		$	3.26			$	2.45
Diluted		$	3.25			$	2.43
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic			49.8				50.1
Diluted			50.0				50.4
Cash dividends per common share		$	0.20			$	0.20

PRELIMINARY CONSOLIDATED STATEMENTS OF CASH FLOWS (in millions) (Unaudited)
		Three Months Ended
		September 30,
			2026				2025
OPERATING ACTIVITIES
Net income		$	162.5			$	122.5
Adjustments to reconcile net income to net cash provided from operating activities:
Depreciation and amortization			36.6				36.0
Deferred income taxes			11.6				5.8
Net pension expense			1.5				3.6
Share-based compensation expense			6.4				5.6
Net loss on disposals of property, plant and equipment			0.3				0.3
Changes in working capital and other:
Accounts receivable			(18.7	)			(36.2	)
Inventories			(61.6	)			15.6
Other current assets			(13.3	)			7.7
Accounts payable			24.1				(27.0	)
Accrued liabilities			(88.5	)			(85.9	)
Pension plan contributions			(8.6	)			(5.9	)
Other postretirement plan contributions			(0.7	)			(0.9	)
Other, net			1.2				(2.0	)
Net cash provided from operating activities			52.8				39.2
INVESTING ACTIVITIES
Purchases of property, plant, equipment and software			(77.7	)			(42.6	)
Proceeds from disposals of property, plant and equipment			0.1				—
Net cash used for investing activities			(77.6	)			(42.6	)
FINANCING ACTIVITIES
Dividends paid			(9.9	)			(10.1	)
Purchases of treasury stock			(133.9	)			(49.1	)
Proceeds from stock options exercised			0.4				0.5
Withholding tax payments on share-based compensation awards			(65.2	)			(45.5	)
Net cash used for financing activities			(208.6	)			(104.2	)
Effect of exchange rate changes on cash and cash equivalents			(0.4	)			0.1
DECREASE IN CASH AND CASH EQUIVALENTS			(233.8	)			(107.5	)
Cash and cash equivalents at beginning of year			393.3				315.5
Cash and cash equivalents at end of period		$	159.5			$	208.0

PRELIMINARY CONSOLIDATED BALANCE SHEETS (in millions) (Unaudited)
		September 30,				June 30,
			2026				2026
ASSETS
Current assets:
Cash and cash equivalents		$	159.5			$	393.3
Accounts receivable, net			722.2				701.9
Inventories			884.4				822.9
Other current assets			76.0				63.1
Total current assets			1,842.1				1,981.2
Property, plant, equipment and software, net			1,538.0				1,487.9
Goodwill			227.3				227.3
Other intangibles, net			2.4				3.9
Deferred income taxes			5.5				5.5
Other assets			129.4				132.5
Total assets		$	3,744.7			$	3,838.3
LIABILITIES
Current liabilities:
Accounts payable		$	345.3			$	313.4
Accrued liabilities			122.2				206.6
Total current liabilities			467.5				520.0
Long-term debt			691.0				690.7
Accrued pension liabilities			82.4				89.6
Accrued postretirement benefits			21.7				22.2
Deferred income taxes			207.4				196.9
Other liabilities			91.9				91.3
Total liabilities			1,561.9				1,610.7
STOCKHOLDERS’ EQUITY
Common stock			286.8				286.8
Capital in excess of par value			341.8				357.1
Reinvested earnings			2,352.3				2,199.7
Common stock in treasury, at cost			(772.5	)			(595.6	)
Accumulated other comprehensive loss			(25.6	)			(20.4	)
Total stockholders’ equity			2,182.8				2,227.6
Total liabilities and stockholders’ equity		$	3,744.7			$	3,838.3

PRELIMINARY SEGMENT FINANCIAL DATA (in millions) (Unaudited)
		Three Months Ended
		September 30,
			2026				2025
Net sales:
Specialty Alloys Operations
Net sales excluding surcharge		$	573.5			$	533.9
Surcharge			156.9				125.7
Specialty Alloys Operations net sales			730.4				659.6
Performance Engineered Products
Net sales excluding surcharge			83.0				87.2
Surcharge			8.1				6.4
Performance Engineered Products net sales			91.1				93.6
Intersegment
Net sales excluding surcharge			(21.7	)			(18.0	)
Surcharge			(1.6	)			(1.5	)
Intersegment net sales			(23.3	)			(19.5	)
Consolidated net sales		$	798.2			$	733.7
Operating income (loss):
Specialty Alloys Operations		$	216.3			$	170.7
Performance Engineered Products			7.3				9.4
Corporate			(26.1	)			(26.6	)
Intersegment			(1.1	)			(0.2	)
Consolidated operating income		$	196.4			$	153.3

The Company has two reportable segments, Specialty Alloys Operations (“SAO”) and Performance Engineered Products (“PEP”).

The SAO segment is comprised of Carpenter’s major premium alloy and stainless steel manufacturing operations. This includes operations performed at mills primarily in Reading and Latrobe, Pennsylvania and surrounding areas as well as South Carolina and Alabama.

The PEP segment is comprised of the Company’s differentiated operations. This segment includes the Dynamet titanium business, the Carpenter Additive business and the Latrobe and Mexico distribution businesses. The businesses in the PEP segment are managed with an entrepreneurial structure to promote flexibility and agility to quickly respond to market dynamics. It is our belief this model will ultimately drive overall revenue and profit growth.

Corporate costs are comprised of executive and director compensation, and other corporate facilities and administrative expenses not allocated to the segments. Also included are items that management considers not representative of ongoing operations and other specifically-identified income or expense items.

The service cost component of net pension expense, which represents the estimated cost of future pension liabilities earned associated with active employees, is included in the operating results of the business segments. The residual net pension expense is included in other income, net, and is comprised of the expected return on plan assets, interest costs on the projected benefit obligations of the plans, amortization of actuarial gains and losses and prior service costs.

PRELIMINARY NON-GAAP FINANCIAL MEASURES (in millions, except per share data) (Unaudited)
ADJUSTED OPERATING MARGIN EXCLUDING SURCHARGE REVENUE		Three Months Ended
		September 30,
			2026				2025
Net sales		$	798.2			$	733.7
Less: surcharge revenue			163.4				130.6
Net sales excluding surcharge revenue		$	634.8			$	603.1
Operating income		$	196.4			$	153.3
Operating margin			24.6	%			20.9	%
Adjusted operating margin excluding surcharge revenue			30.9	%			25.4	%

ADJUSTED SEGMENT OPERATING MARGIN EXCLUDING SURCHARGE REVENUE		Three Months Ended
		September 30,
			2026				2025
Specialty Alloys Operations
Net sales		$	730.4			$	659.6
Less: surcharge revenue			156.9				125.7
Net sales excluding surcharge revenue		$	573.5			$	533.9
Operating income		$	216.3			$	170.7
Operating margin			29.6	%			25.9	%
Adjusted operating margin excluding surcharge revenue			37.7	%			32.0	%

ADJUSTED SEGMENT OPERATING MARGIN EXCLUDING SURCHARGE REVENUE		Three Months Ended
		September 30,
			2026				2025
Performance Engineered Products
Net sales		$	91.1			$	93.6
Less: surcharge revenue			8.1				6.4
Net sales excluding surcharge revenue		$	83.0			$	87.2
Operating income		$	7.3			$	9.4
Operating margin			8.0	%			10.0	%
Adjusted operating margin excluding surcharge revenue			8.8	%			10.8	%

Management believes that removing the impact of raw material surcharge from operating margin provides a more consistent basis for comparing results of operations from period to period, thereby permitting management to evaluate performance and investors to make decisions based on the ongoing operations of the Company. Management uses its results excluding this amount to evaluate its operating performance and to discuss its business with investment institutions, the Company’s board of directors and others.

		Three Months Ended
		September 30,
FREE CASH FLOW			2026				2025
Net cash provided from operating activities		$	52.8			$	39.2
Purchases of property, plant, equipment and software			(77.7	)			(42.6	)
Proceeds from disposals of property, plant and equipment			0.1				—
Free cash flow		$	(24.8	)		$	(3.4	)

Management believes that the presentation of free cash flow provides useful information to investors regarding our financial condition because it is a measure of cash generated which management evaluates for alternative uses. It is management’s current intention to use excess cash to fund investments in capital equipment, acquisition opportunities and consistent dividend payments. Additionally, we will discretionarily use excess cash for a share repurchase program up to $1.0 billion of our outstanding common stock. Free cash flow is not a U.S. GAAP financial measure and should not be considered in isolation of, or as a substitute for, cash flows calculated in accordance with U.S. GAAP.

PRELIMINARY SUPPLEMENTAL SCHEDULE (in millions) (Unaudited)
		Three Months Ended
		September 30,
NET SALES BY END-USE MARKET		2026			2025
End-Use Market Excluding Surcharge Revenue:
Aerospace and Defense		$	425.4		$	388.3
Medical			51.7			61.6
Energy			32.9			42.5
Transportation			19.8			17.9
Industrial and Consumer			83.2			75.0
Distribution			21.8			17.8
Total net sales excluding surcharge revenue			634.8			603.1
Surcharge revenue			163.4			130.6
Total net sales		$	798.2		$	733.7

Investor Inquiries:		Media Inquiries:
John Huyette		Heather Beardsley
+1 610-208-2061		+1 610-208-2278
jhuyette@cartech.com		hbeardsley@cartech.com